Evidence map›Paper›PMID 29237492›Full record

ArticleStem cell research & therapy2017

Pentosan polysulfate binds to STRO-1

Jiehua Wu, Susan Shimmon, Sharon Paton, Christopher Daly, Tony Goldschlager, Stan Gronthos, Andrew C W Zannettino, Peter Ghosh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Jiehua WuProteobioactives Pty. Ltd., PO Box 174, Balgowlah, Sydney, New South Wales, 2093, Australia.
Susan ShimmonProteobioactives Pty. Ltd., PO Box 174, Balgowlah, Sydney, New South Wales, 2093, Australia.
Sharon PatonMyeloma Research Laboratory, Faculty of Health and Medical Sciences, University of Adelaide and the Cancer Theme, South Australia Health and Medical Research Institute, Adelaide, South Australia, 5000, Australia.
Christopher DalyDepartment of Surgery, Monash University, Clayton, Victoria, 3168, Australia.
Tony GoldschlagerDepartment of Surgery, Monash University, Clayton, Victoria, 3168, Australia.
Stan GronthosMesenchymal Stem Cell Laboratory, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, 5000, Australia.
Andrew C W ZannettinoMyeloma Research Laboratory, Faculty of Health and Medical Sciences, University of Adelaide and the Cancer Theme, South Australia Health and Medical Research Institute, Adelaide, South Australia, 5000, Australia.
Peter GhoshProteobioactives Pty. Ltd., PO Box 174, Balgowlah, Sydney, New South Wales, 2093, Australia. biopartners@tpg.com.au.
Hudson Institute of Medical Research · AUUniversity of Adelaide · AUMacquarie University · AUMonash University · AUSouth Australian Health and Medical Research Institute · AUUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe pharmaceutical agent pentosan polysulfate (PPS) is known to induce proliferation and chondrogenesis of mesenchymal progenitor cells (MPCs) in vitro and in vivo. However, the mechanism(s) of action of PPS in mediating these effects remains unresolved. In the present report we address this issue by investigating the binding and uptake of PPS by MPCs and monitoring gene expression and proteoglycan biosynthesis before and after the cells had been exposed to limited concentrations of PPS and then re-established in culture in the absence of the drug (MPC priming).

methodsImmuno-selected STRO-1

resultsThe kinetic studies indicated that, in culture, PPS rapidly binds to MPC surface receptors, followed by internalisation and localization within the nucleus of the cells. Following PPS-priming of MPCs and a further 48 h of culture, both cell proliferation and proteoglycan synthesis were enhanced. Reduced expression of MPC-related cell surface antigen expression was promoted by the PPS priming, and RNA sequencing analysis revealed changes in the expression of 42 genes.

conclusionThis study has shown that priming of MPCs with low concentrations of PPS enhanced chondrogenesis and MPC proliferation by modifying their characteristic basal gene and protein expression. These findings offer a novel approach to re-programming mesenchymal stem cells for clinical indications which require the repair or regeneration of cartilaginous tissues such as in osteoarthritis and degenerative disc disease.

Indexed as

Antigens, SurfaceBiological TransportBiomarkersBone Marrow CellsCell DifferentiationCell ProliferationChondrocytesChondrogenesisGene Expression ProfilingGene Expression RegulationHumansMesenchymal Stem CellsMolecular Sequence AnnotationPentosan Sulfuric PolyesterProteoglycansAntigens, SurfaceBiomarkersPentosan Sulfuric PolyesterProteoglycansSTRO-1 antigen, humanCD146ChondrogenesisGene expressionHeparinMesenchymal progenitor cellsPentosan polysulfateProliferation

Identifiers

PMID29237492
PMCPMC5729458
OpenAlexW2773897091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.